Cardiac fibrosis
Top Cited Papers
Open Access
- 2 November 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 117 (6), 1450-1488
- https://doi.org/10.1093/cvr/cvaa324
Abstract
Myocardial fibrosis, the expansion of the cardiac interstitium through deposition of extracellular matrix proteins, is a common pathophysiologic companion of many different myocardial conditions. Fibrosis may reflect activation of reparative or maladaptive processes. Activated fibroblasts and myofibroblasts are the central cellular effectors in cardiac fibrosis, serving as the main source of matrix proteins. Immune cells, vascular cells and cardiomyocytes may also acquire a fibrogenic phenotype under conditions of stress, activating fibroblast populations. Fibrogenic growth factors (such as transforming growth factor-β and platelet-derived growth factors), cytokines [including tumour necrosis factor-α, interleukin (IL)-1, IL-6, IL-10, and IL-4], and neurohumoral pathways trigger fibrogenic signalling cascades through binding to surface receptors, and activation of downstream signalling cascades. In addition, matricellular macromolecules are deposited in the remodelling myocardium and regulate matrix assembly, while modulating signal transduction cascades and protease or growth factor activity. Cardiac fibroblasts can also sense mechanical stress through mechanosensitive receptors, ion channels and integrins, activating intracellular fibrogenic cascades that contribute to fibrosis in response to pressure overload. Although subpopulations of fibroblast-like cells may exert important protective actions in both reparative and interstitial/perivascular fibrosis, ultimately fibrotic changes perturb systolic and diastolic function, and may play an important role in the pathogenesis of arrhythmias. This review article discusses the molecular mechanisms involved in the pathogenesis of cardiac fibrosis in various myocardial diseases, including myocardial infarction, heart failure with reduced or preserved ejection fraction, genetic cardiomyopathies, and diabetic heart disease. Development of fibrosis-targeting therapies for patients with myocardial diseases will require not only understanding of the functional pluralism of cardiac fibroblasts and dissection of the molecular basis for fibrotic remodelling, but also appreciation of the pathophysiologic heterogeneity of fibrosis-associated myocardial disease.Keywords
Funding Information
- NIH (R01 HL76246, R01 HL85440, R01 HL149407)
- U.S. Department of Defense (PR151134, PR151029, PR181464)
This publication has 612 references indexed in Scilit:
- The Mechanical Environment Modulates Intracellular Calcium Oscillation Activities of MyofibroblastsPLOS ONE, 2013
- p38 MAPK alpha mediates cytokine-induced IL-6 and MMP-3 expression in human cardiac fibroblastsBiochemical and Biophysical Research Communications, 2013
- A TRPC6-Dependent Pathway for Myofibroblast Transdifferentiation and Wound Healing In VivoDevelopmental Cell, 2012
- The role of inflammatory and fibrogenic pathways in heart failure associated with agingHeart Failure Reviews, 2010
- Prognostic Value of Myocardial Infarct Size and Contractile Reserve Using Magnetic Resonance ImagingJournal of the American College of Cardiology, 2009
- The role of IL-1 in the pathogenesis of heart diseaseArchivum Immunologiae et Therapiae Experimentalis, 2009
- Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overloadHistochemistry and Cell Biology, 2008
- Aging-Related Defects Are Associated With Adverse Cardiac Remodeling in a Mouse Model of Reperfused Myocardial InfarctionJournal of the American College of Cardiology, 2008
- Cellular and molecular mechanisms of fibrosisThe Journal of Pathology, 2007
- Interleukin-10 is not a critical regulator of infarct healing and left ventricular remodelingCardiovascular Research, 2007